Ola Landgren, MD, PhD, of the Sylvester Comprehensive Cancer Center, joins Blood Cancers Today to discuss quadruplet therapy in newly diagnosed multiple myeloma (MM).

Dr. Landgren was the discussant for a session titled “The More the Better? Quadruplets in Newly Diagnosed Multiple Myeloma” at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. The session included three trials that studied the following combinations:

1. Isatuximab plus VRd versus VRd in transplantineligible patients
2. Isatuximab plus VRd versus isatuximab plus Rd in transplantineligible patients
3. Daratumumab plus VRd in transplanteligible patients

“What was striking to me as the discussant is that however you look at it—from a transplanteligible or transplantineligible perspective—it’s obvious that adding the fourth drug will improve outcomes,” Dr. Landgren said. “We are now at the point of narrowing the gap between these two groups.”

Dr. Landgren further discussed how quadruplet therapy is changing the MM treatment landscape, especially by deepening responses and prolonging progressionfree and overall survival.

“With modern, immunotherapybased, effective therapies, we can deliver good outcomes to all patients independent of age or performance status,” he said.